Close

JPMorgan Downgrades AnaptysBio (ANAB) to Underweight, Following Clinical Update

March 8, 2021 12:04 PM EST Send to a Friend
JPMorgan analyst Anupam Rama downgraded AnaptysBio (NASDAQ: ANAB) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login